P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
Aldo M. Roccaro,Irene M. Ghobrial,Simona Blotta,Steven P. Treon,Michele Malagola,Kenneth C. Anderson,Paul G. Richardson,Domenico Russo +7 more
TL;DR: The success of targeted therapy in MM has since led to the development and investigation of more than 30 new compounds in this disease and in other plasma cell dyscrasias such as Waldenström’s macroglobulinemia and primary amyloidosis, both in the preclinical settings and as part of clinical trials.
Journal ArticleDOI
Does maintenance therapy with thalidomide benefit patients with multiple myeloma
TL;DR: Patients received high-dose vincristine, doxorubicin and dexamethasone chemotherapy (VAD regimen) followed by double autologous stem cell transplantation and were randomly assigned to one of three treatment arms until disease progression.
Journal ArticleDOI
Killing of Drug-Sensitive and Resistant Myeloma Cells and Disruption of Their Bone Marrow Stromal Interaction by HuLuc63, a Novel Humanized Anti-CS1 Monoclonal Antibody.
Yu-Tzu Tai,Weihua Song,Xian-Feng Li,Peter C. Burger,Robert L. Schlossman,Audie Rice,Anne van Abbema,Paul G. Richardson,Nikhil C. Munshi,Daniel E. H. Afar,Kenneth C. Anderson +10 more
TL;DR: The novel humanized anti-CS1 mAb, HuLuc63, induced significant cytotoxicity against MM cells including drug-resistant cells, and inhibited their interaction with BMSCs.
Journal ArticleDOI
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Kazutaka Sunami,Kosei Matsue,Kenshi Suzuki,Naoki Takezako,Atsushi Shinagawa,Sanae Sakurai,Hiromi Tamakoshi,Tsvetan Biyukov,Teresa Peluso,Paul G. Richardson +9 more
TL;DR: The clinical benefit of PVd in Japanese patients with relapsed or refractory multiple myeloma is consistent with those in the overall OPTIMISMM patient population and the safety profile was as expected for PVd.